RUNX2 and acute myeloid leukemia: Most importantly, all generated RevTMs were able to bind to CD33 or CD123 antigens on the AML cell lines MOLM-13 and OCI-AML3 as well as to the RevCARs on the RevCAR-E5B9-28/3z or RevCAR-E7B6-28/3z T-cells as shown in Figure 2b,d.